Ownership and insider activity for Kazia Therapeutics Ltd ADR (KZIA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous...
Price
| Price | $10.20 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | AU |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-01-08 | Coffey Steven R. S. | A-Award | 100,000 | $910K |
| 2026-01-08 | Friend John E. II | A-Award | 500,000 | $3.4M |
| 2026-01-08 | Friend John E. II | A-Award | 150,000 | |
| 2026-01-08 | Bonacorda Jeffrey | A-Award | 150,000 | $1.0M |
| 2026-01-08 | Davidson Ebru | A-Award | 100,000 | $910K |
| 2026-01-08 | Cain David | A-Award | 100,000 | $910K |
| 2026-01-08 | APPLE ROBERT F | A-Award | 75,000 | $508K |
| 2026-06-19 | Levine James E. | A-Award | 200,000 | $2.8M |
| 2026-06-19 | Rao Sudha | A-Award | 250,000 | $4.6M |
| 2026-06-01 | Levine James E. |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33.5M | $14.5M | $6.0M | $5.4M | $8.8M | $27.6M | $7.4M | $5.2M | $1.7M | $4.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $91000 | $5067 | $1130 | $1.6M | $439 | 0 | $51000 | $105000 | $133000 | $90000 |
| Inventory | $434000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $34.1M | $19.5M | $9.3M | $7.5M | $10.7M | $29.4M | $9.4M | $10.8M | $6.1M | $4.9M |
| Property, Plant & Equipment | $592000 | $489605 | $1000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $822000 | $15.9M | $14.6M | $13.5M | $12.4M | $22.0M | $19.1M | $17.3M | $15.4M | $1.1M |
| Total Assets | $35.5M | $35.9M | $28.2M | $21.2M | $23.1M | $58.1M | $35.9M | $28.1M | $21.6M | $6.1M |
| Accounts Payable | $512000 | $1.2M | $1.4M | $1.1M | $1.7M | $1.9M | $1.5M | $857000 | $4.5M | $5.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $1.8M | $1.8M | $634000 | $396000 |
| Total Current Liabilities | $1.4M | $5.4M | $3.9M | $2.2M | $5.1M | $8.3M | $6.7M | $7.6M | $25.8M | $14.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.6M | $10.6M | $8.9M | $7.0M | $8.9M | $20.2M | $17.6M | $16.0M | $31.6M | $14.4M |
| Retained Earnings | -$160.5M | -$171.0M | -$14.6M | -$24.9M | -$36.2M | -$44.2M | -$68.6M | -$89.1M | -$115.1M | -$134.8M |
| Total Equity | $33.9M | $25.3M | $19.2M | $14.2M | $14.1M | $37.9M | $18.3M | $12.1M | -$10.0M | -$8.3M |
| Total Debt | $10000 | $10000 | $84000 | 0 | 0 | 0 | $1.8M | $1.8M | $634000 | $396000 |
| Net Debt | -$33.4M | -$14.4M | -$5.9M | -$5.5M | -$8.8M | -$27.6M | -$5.5M | -$3.4M | -$1.0M | -$3.9M |
| Working Capital | $32.7M | $14.1M | $5.4M | $5.3M | $5.6M | $21.1M | $2.7M | $3.2M | -$19.7M | -$9.1M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 2.87 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -40.25 |
Profitability
| Return on Equity | -116.86% |
| Return on Invested Capital | -36.21% |
| Return on Assets | -31.35% |
| Gross Margin | 100.00% |
| Operating Margin | -92086.45% |
| Net Margin | -113004.58% |
Related companies: BDRX · CANF · CMND · CNSP · GRI · INM · OGEN
Explore sector: Healthcare · Biotechnology
More sections of KZIA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks